EWM
FENC icon

Edge Wealth Management’s Fennec Pharmaceuticals FENC Stock Holding History

Edge Wealth Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-502
Closed -$4K – 581
2018
Q3 		$4K Hold
502
– – ﹤0.01% 521
2018
Q2 		$5K Hold
502
– – ﹤0.01% 487
2018
Q1 		$6K Buy
+502
New +$4.74K ﹤0.01% 435

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Edge Wealth Management's FENC Position: Q4 2018 in Review

Edge Wealth Management sold out of Fennec Pharmaceuticals (FENC) in Q4 2018, closing a stake of 502 shares — an estimated $4K sold.

Edge Wealth Management first reported a position in FENC in Q1 2018 and held it in 3 quarters. The position peaked at $6K in Q1 2018. 47 funds tracked by Wall St. Rank hold FENC as of Q4 2018.

  • Edge Wealth Management reported no remaining Fennec Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Edge Wealth Management sold 502 Fennec Pharmaceuticals shares in Q4 2018, an estimated $4K.
  • Edge Wealth Management first reported a position in Fennec Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Edge Wealth Management's Fennec Pharmaceuticals position peaked at $6K in Q1 2018.
  • 47 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2018.

Based on Edge Wealth Management's 13F filing for Q4 2018, filed 11 Jan 2019.